ABSTRACT
Background: Quality of life (QOL) is important in patients of epilepsy as it is affected both by disease as well as therapy. QOL is the most overlooked component of antiepileptic treatment.Methods: An observational analytical study was conducted in the Department of Pharmacology in collaboration with Department of Neurology of Himalayan Institute of Medical Science, Dehradun over 12 months. 80 patients satisfying inclusion criteria were enrolled and divided into two groups based on physician discretion and followed up for 12 weeks. Patients were evaluated at 0 and 12 weeks for quality of life using QOLIE-10 self-administered questionnaire, they were also assessed for seizure control and drug related adverse effects.Results: 60 patients were enrolled and divided into two treatment groups as per physician discretion, levetiracetam (30) and valproic acid (30) groups. Study groups showed significant improvement in QOL (mean change in QOL17.95�527 for LEV and 11.56�540 for VPA). Levetiracetam (LEV) group showed significant improvement over valproic acid (VPA) group (p=0.05) at 12 weeks. Patients who achieved total seizure control at 6 weeks were 93.33% patients in levetiracetam and 90% in valproic acid group, reason being non adherence which was 6.67% and 10% respectively. Adverse event recorded with levetiracetam (03), most common being drowsiness and with valproic acid (08), with most common being anorexia.Conclusions: Levetiracetam therapy has led to better quality of life and has the same seizure control as valproic acid, and has shown to have lower incidence of adverse effect.
ABSTRACT
Background: Quality of life plays an important role in patients of epilepsy and is the most neglected part during management. The antiepileptic drugs treatment results in seizure control but adversely affect the quality of life in patients.Methods: An observational analytical study was conducted in the Department of pharmacology with Department of Neurology of Himalayan Institute of Medical Sciences, Dehradun over 12 months. 85 patients fulfilling the inclusion criteria with diagnosis of generalized tonic clonic seizures (GTCS) were enrolled and divided into two groups based on physicians discretion and followed up for 12 weeks. Patients were evaluated for quality of life by QOLIE-10 self administered questionnaire at 0 and 12 weeks, assessed for seizure control and drug related adverse effects.Results: 85 patients were enrolled and divided into two treatment arms as per physician discretion, levetiracetam (41) and valproic acid group (44). Study drugs showed significant improvement in quality of life, levetiracetam showed mean change that was significantly greater than valproic acid (p=0.003) at 12 weeks. Patients who failed to achieve seizure control at 6 weeks were 17% patients in levetiracetam and 20% in valproic acid group, reason being non-adherence which was 17% and 20% respectively. Adverse events recorded with Levetiracetam (10), most common being increased sleep and with valproic acid (18), with most common being increased sleep and weight gain.Conclusions: Levetiracetam treatment resulted in better quality of life, with similar seizure control but decreased number of adverse effect then Valproic acid.
ABSTRACT
Introducción: en el mundo aproximadamente 50 millones de personas presentan epilepsia, La enfermedadgenera una gran secuela en el paciente, y en las familias con esta enfermedad.Objetivo: describir condiciones que afecten la calidad de vida, mediante el formulario QOLIE-10, en lospacientes con epilepsia valorados en el Hospital de San José en Bogotá.Materiales y métodos: estudio observacional descriptivo de corte transversal a partir de la encuesta decalidad de vida en epilepsia (QOLIE-10). La información se resumió con frecuencias y medidas de tendenciacentral y de dispersión.Resultados: se realizaron 157 encuestas. Según la clasificación del QOLIE 10, 43,3% de los pacientes presentaronmala calidad de vida, por lo cual, sumada la calificación regular (19,8%), se interpreta que la mayoría depacientes no tienen buena calidad de vida. La calidad de vida, al igual que en el resto de la población mundial,se ve afectada por la frecuencia ictal.Conclusión: en la población de pacientes con epilepsia su calidad de vida no es buena a pesar de que 71%son tratados con monoterapia y tienen control de la enfermedad.
Introduction: in the world about 50 million people have epilepsy, the disease causes a great sequel to the patient, and families with this diseaseObjective: to describe conditions that affect the quality of life by QOLIE-10 form in patients with epilepsy, valued at San José Hospital of Bogotá.Materials and methods: cross-sectional descriptive observation from the survey of quality of life in epilepsy (QOLIE-10). The information was summarized using frequencies, measures of central tendency and dispersion.Results: 157 surveys were obtained. According to the classification of QOLIE 10, 43.3% of patients had poor quality of life, which along with the regular grade (19.8%) is interpreted that most patients do not have a good quality of life. Quality of life as in the rest of the world population is affected by the ictal frequency.Conclusion: in patients with epilepsy Population their quality of life is not good although 71% are on monotherapy and have control of the disease.
Subject(s)
Humans , Cross-Sectional Studies , Epilepsy , Neurology , Quality of LifeABSTRACT
BACKGROUND AND PURPOSE: It is necessary in clinical practice to screen patients with epilepsy for quality-of-life factors. The purpose of this study was to develop a Korean version of the Quality of Life in Epilepsy (QOLIE)-10 survey and to determine its reliability and validity. METHODS: Data were collected from 397 adult epilepsy patients. The ten items of QOLIE-10 were derived from the Korean version of QOLIE-31. We assessed factor analysis, internal consistency, test-retest reliabilities, construct validity, and discriminant validity. Test-retest was performed in 97 patients. RESULTS: The ten items of QOLIE-10 were grouped into two factors: epilepsy effects/role function (driving, social, work, physical effect, mental effect, and memory) and mental health (overall quality of life, depression, and energy). The internal consistency reliability coefficient (Cronbach's alpha) was 0.843 for epilepsy effects/role function and 0.606 for the mental-health scale. Test - retest data revealed statistically significant correlations for individual items (range, r=0.66-0.38) and scales (range, r=0.63-0.48), except for one item, driving (r=0.21, p=0.133). QOLIE-10 was significantly correlated with the source scales in the Korean version of QOLIE-31 and with several external measures. The QOLIE-10 scores discriminated between patient groups according to their seizure severity and level of education. CONCLUSIONS: QOLIE-10 was derived from the Korean version of QOLIE-31. The results of this study show that QOLIE-10 can be applied as a screening measure of quality of life in Korean epilepsy patients.